PAVMEDLOGONEW15OCT2018.png
PAVmed Provides Business Update and Preliminary Fourth Quarter 2020 Financial Results
February 22, 2021 08:18 ET | PAVmed Inc.
Announces majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company Lucid Diagnostics to launch major new multi-channel commercialization initiative for its...
PAVMEDLOGONEW15OCT2018.png
PAVmed Reschedules Business Update Conference Call on February 22, 2021 to 8:30 AM EST
February 18, 2021 09:30 ET | PAVmed Inc.
Conference call and live webcast was previously scheduled for 4:30 PM EST Lucid Diagnostics strategic advisor and medical diagnostics pioneer Stanley Lapidus to join call NEW YORK, Feb. 18, 2021 ...
First U.S. Patient Undergoes Successful Minimally Invasive Carpal Tunnel Release Using PAVmed’s CarpX® Device
February 16, 2021 09:30 ET | PAVmed Inc.
NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today...
PAVMEDLOGONEW15OCT2018.png
PAVmed to Hold Business Update Conference Call on February 22, 2021
February 09, 2021 09:30 ET | PAVmed Inc.
NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVMEDLOGONEW15OCT2018.png
PAVmed Closes $13.4 Million Common Stock Registered Direct Offering Priced At-the-Market under Nasdaq Rules
January 08, 2021 10:53 ET | PAVmed Inc.
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVMEDLOGONEW15OCT2018.png
PAVmed Announces Registered Direct Offering of its Common Stock Priced At-the-Market under Nasdaq Rules
January 06, 2021 09:29 ET | PAVmed Inc.
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVMEDLOGONEW15OCT2018.png
PAVmed Closes Additional $8.1 Million Common Stock Registered Direct Offering
December 22, 2020 12:04 ET | PAVmed Inc.
NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVMEDLOGONEW15OCT2018.png
PAVmed Announces Pricing of Additional $8.1 Million Common Stock Registered Direct Offering
December 18, 2020 09:29 ET | PAVmed Inc.
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVMEDLOGONEW15OCT2018.png
PAVmed Announces Registered Direct Offering of its Common Stock
December 11, 2020 09:29 ET | PAVmed Inc.
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVMEDLOGONEW15OCT2018.png
PAVmed Reports Third Quarter 2020 Financial Results and Provides Business Update
November 17, 2020 16:00 ET | PAVmed Inc.
Conference call to be held today at 4:30 p.m. Eastern time NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly...